Vera Therapeutics, Inc.

NasdaqGM VERA

Vera Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -16.30

Vera Therapeutics, Inc. Price to Earnings Ratio (P/E) is -16.30 on January 14, 2025, a -81.04% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Vera Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -7.99 on January 18, 2024, which is 50.98% above the current Price to Earnings Ratio (P/E).
Vera Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -28.06 on May 07, 2024, which is -72.12% below the current Price to Earnings Ratio (P/E).
Vera Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -21.60.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: VERA

Vera Therapeutics, Inc.

CEO	Dr. Marshall W. Fordyce M.D.
IPO Date	May 14, 2021
Location	United States
Headquarters	8000 Marina Boulevard
Employees	82
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Key trends

Past 5 years